Deucrictibant / FDA decision

Research only

Rx-PHVS-2704 · April 23, 2027 sponsor target

Sponsor source Resolution draft Program evidence

Event question

Will the FDA approve Deucrictibant for on-demand treatment of hereditary angioedema attacks?

Sponsor describes an oral small-molecule B2 antagonist, RAPIDe-3 and an April 23, 2027 FDA target.

Sponsor target: April 23, 2027
Source published: Jul 6, 2026
Research snapshot: Oct 28, 2026
Trading status: Research / unlisted

A PDUFA goal date is not an approval determination or a trading cutoff. Application scope, delays and invalid-result terms require reviewed rules.

Published evidence

2 publications2 exact-program0 related1 context / correction notes

Review publications

Sources

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sponsor-releaseir.pharvaris.com

Sponsor describes an oral small-molecule B2 antagonist, RAPIDe-3 and an April 23, 2027 FDA target.

Published: Jul 6, 2026
Retrieved: 2026-10-30 02:09:48 UTC

clinical-trial-registryclinicaltrials.gov

Registry identifies the associated compound, condition and sponsor; trial completion is separate from FDA action.

Published: Not supplied
Retrieved: 2026-10-30 02:09:48 UTC

Resolution not committed

This research candidate has no onchain question, committed rule hash or funded pool.

Draft outcome criteria

These terms require review and cannot resolve a market.

YES: Approval of the exact application, formulation and eligible indication, established under the reviewed evidence hierarchy. Application and label scope still require review.
NO: Final terms must specify a Complete Response Letter, withdrawal, extension and no decision by cutoff. The sponsor’s target date alone cannot establish NO.
INVALID: Final terms must specify ambiguous identity, erroneous dates and unsupported evidence. No policy has been committed for this candidate.

Read the full research draft

RESEARCH DRAFT / NOT FINAL RULES / NOT COMMITTED

Program: Deucrictibant
Sponsor: Pharvaris
Indication under review: on-demand treatment of hereditary angioedema attacks
Event: FDA marketing-approval decision
Sponsor target: 2027-04-23 (date only, not a trading cutoff)

YES: FDA approval of the exact application, formulation and eligible indication, established under a reviewed evidence hierarchy. Exact application/label scope requires review.

NO: The approved market terms must specify treatment of a Complete Response Letter, withdrawal, extension and no decision by cutoff. No automatic NO outcome is inferred from the sponsor target date.

INVALID: The approved terms must specify erroneous dates, ambiguous identity, unsupported evidence and withdrawal handling. No policy has been committed for this candidate.

Cutoff and timezone: UNSET / OWNER APPROVAL REQUIRED.
Evidence: FDA approval letter or other authoritative FDA record; sponsor disclosures require the corroboration specified in final rules.
Oracle: assertion, dispute bond, liveness and final settlement require separately reviewed deployment settings.

This draft cannot resolve a market or pay a claim. Publish reviewed canonical bytes and their keccak256 commitment before listing.

No question ID, approved deadline or UMA assertion exists for this research candidate. Sandbox claims have no redemption rights.